Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market - The ASCO Post
Opdivo was granted accelerated approval in 2018 for small cell lung cancer based on surrogate endpoints, but has now been withdrawn from the US market, having failed to achieve its primary endpoint of Overall Survival in confirmatory studies.
This emphasises the urgent need that BMS and Merck have to find ways to make Opdivo and Keytruda work in more patients and in more forms of cancer.
BMS woes continue
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
